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Background: The awareness is growing that central sensitization is of prime 
importance for the assessment and management of chronic pain, but its classification 
is challenging clinically since no gold standard method of assessment exists. 
Objectives: Designing the first set of classification criteria for the classification of 
central sensitization pain. 
Methods: A body of evidence from original research papers was used by 18 pain 
experts from 7 different countries to design the first classification criteria for central 
sensitization pain. 
Results: It is proposed that the classification of central sensitization pain entails 2 major 
steps: the exclusion of neuropathic pain and the differential classification of nociceptive 
versus central sensitization pain. For the former, the International Association for the 
Study of Pain diagnostic criteria are available for diagnosing or excluding neuropathic 
pain. For the latter, clinicians are advised to screen their patients for 3 major classification 
criteria, and use them to complete the classification algorithm for each individual 
patient with chronic pain. The first and obligatory criterion entails disproportionate 
pain, implying that the severity of pain and related reported or perceived disability are 
disproportionate to the nature and extent of injury or pathology (i.e., tissue damage 
or structural impairments). The 2 remaining criteria are 1) the presence of diffuse pain 
distribution, allodynia, and hyperalgesia; and 2) hypersensitivity of senses unrelated to 
the musculoskeletal system (defined as a score of at least 40 on the Central Sensitization 
Inventory). 
Limitations: Although based on direct and indirect research findings, the classification 
algorithm requires experimental testing in future studies.
Conclusion: Clinicians can use the proposed classification algorithm for differentiating 
neuropathic, nociceptive, and central sensitization pain.   
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Many chronic pain patients, including those with persisting neck pain (1-4), pelvic pain (5,6), low back pain (7-9), fibromyalgia 
(8,10,11), subacromial impingement syndrome (12), 
chronic fatigue syndrome (13), tension-type headache 
(14), migraine (15), osteoarthritis (8,16,17), rheumatoid 
arthritis (18), tennis elbow (19,20), nonspecific arm 
pain (21), and patella tendinopathy (22) show features 
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in patients with chronic pain although larger trials are 
required to further substantiate these findings. Finally, 
the clinical importance of CS is supported by findings 
in chronic low back pain patients. Compared to those 
classified as having peripheral neuropathic pain and 
nociceptive pain, patients with CS reported more severe 
pain, poorer general health-related quality of life, and 
greater levels of back pain-related disability, depres-
sion, and anxiety (39).
In some patient populations, CS may be the 
characteristic feature of the disorder, as is the case 
with chronic whiplash, fibromyalgia, chronic fatigue 
syndrome, and irritable bowel syndrome (25). Not 
all chronic pain patients have CS, but it may underlie 
sub-groups of patients with chronic low back pain, 
whiplash, osteoarthritis, rheumatoid arthritis, tennis 
elbow pain, shoulder pain, and headache (8,12,14-
18,25,40,41). The reasons for this are unknown, but 
may reflect a genetic predisposition and the influence 
of other biopsychosocial factors. At the group level, 
these populations may be characterized by CS, but at 
the individual level definitely not all patients show evi-
dence of CS. Rather, a subgroup of these populations 
is characterized by CS. If present, CS may dominate the 
clinical picture, modulate the transition to chronicity 
(4,33), and mediate treatment responses (2,20). There-
fore, it may be considered important for clinicians to be 
able to identify or diagnose CS in patient populations 
presenting for treatment. 
While patients with chronic pain are more likely 
to present with CS, CS may not be limited to chronic 
pain states. For example, in patients with whiplash as-
sociated disorders, abnormal sensory processing may 
appear quite rapidly (< 7 days) after the initial whiplash 
trauma, and once present, it has an important predic-
tive ability for the development of chronicity (4,42). 
Hence, it is important for clinicians to rapidly identify 
CS in patients with (sub)acute pain for the early identi-
fication of the risk for chronicity.  
Although awareness is growing that CS may be 
of prime importance in the development, persistence, 
and management of chronic pain, its classification is 
challenging clinically since no gold standard method 
of assessment exists. In recent years, 2 questionnaires 
have been developed for the screening of CS, the Pain 
Sensitivity Questionnaire (43) and the Central Sensiti-
zation Inventory (44,45). These questionnaires assess 
aspects of CS but the inclusion of physical assessment 
measures and clinical judgments by health care profes-
sionals also offer greater potential for the classification 
suggestive of central sensitization (CS), a process 
characterized by generalized hypersensitivity of the 
somatosensory system (23-25). According to Woolf 
(26), CS is “operationally defined as an amplification 
of neural signaling within the central nervous system 
that elicits pain hypersensitivity.” These studies provide 
evidence supporting the presence of CS in patients 
with chronic pain through observational brain imaging 
studies, psychophysical testing with various stimuli, and 
cerebral metabolism studies (5,7,8,12-16,19,20,27).
CS reflects increased activity of pain facilitation 
pathways (11,27) and malfunctioning of descending 
pain inhibitory pathways which result in dysfunctional 
endogenous analgesic control (13). In addition, the 
pain neuromatrix is likely to be overactive in patients 
with CS: Increased activity is present in brain areas 
known to be involved in acute pain sensations and 
emotional representations like the insula, anterior 
cingulate cortex, and the prefrontal cortex, but not in 
the primary or secondary somatosensory cortex (28). 
An overactive pain neuromatrix entails brain activity in 
regions not involved in acute pain sensations including 
various brain stem nuclei, dorsolateral frontal cortex, 
and the parietal associated cortex (28). Research find-
ings also suggest a specific role of the brainstem for the 
maintenance of CS in humans (29). Furthermore, long-
term potentiation of neuronal synapses in the anterior 
cingulate cortex (30), nucleus accumbens, insula, and 
the sensorimotor cortex, as well as decreased gamma-
aminobutyric acid-neurotransmission (31) represent 2 
potential mechanisms contributing to the overactive 
pain neuromatrix. 
As mentioned, the concept of CS has been studied 
extensively in different patient cohorts (1,2-5,8,12-
15,18,19,32), showing that CS may modulate the de-
velopment of pain (e.g., in fibromyalgia) and/or the 
transition from acute to chronic pain (e.g., whiplash 
associated disorder) (4,33) in patients where an obvi-
ous source of nociception is absent. CS in these patient 
groups can also mediate treatment responses (2,20) thus 
inviting clinicians to consider targeting the processes 
underlying CS when treating patients with chronic pain 
(24,34). A limited body of evidence suggests that some 
of the mechanisms underlying CS may be responsive to 
clinical interventions. For example, there is some evi-
dence to suggest that effective treatment for chronic 
low back pain may reverse abnormal brain function 
(35,36), and that biopsychosocially-driven rehabilita-
tion may reduce central nervous system hyperexcit-
ability (37) and increase prefrontal cortical volume (38) 
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of CS. Guidelines for the recognition of CS in patients 
with musculoskeletal pain have been proposed (25), 
and although helpful, they are unable to guide clini-
cians towards clear-cut classification decisions in clinical 
practice. Therefore, a body of evidence from original 
research papers was used by 18 pain experts from 7 dif-
ferent countries to design the first classification criteria 
for CS pain. Here we propose for the first time a set of 
classification criteria for CS pain as an entity relatively 
distinct from other mechanisms-based classifications of 
pain such as neuropathic and nociceptive pain. 
Excluding or Diagnosing Neuropathic Pain as 
the First Important Step
It is proposed that the classification of CS pain en-
tails 2 major steps: the exclusion of neuropathic pain 
and the differential classification of nociceptive versus 
CS pain. 
Neuropathic pain is defined as “pain arising as a 
direct consequence of a lesion or disease affecting the 
somatosensory system” (46). Neuropathic pain can be 
both peripheral (i.e., located in a nerve, dorsal root 
ganglion, or plexus) and central (located in the brain or 
spinal cord). Neuropathic pain is characterized by sen-
sitization as well; peripheral and central (segmentally 
related) pain pathways are hyperexcitable in patients 
with neuropathic pain (47,48). However, here we focus 
on the classification of non-neuropathic CS pain, imply-
ing that exclusion of neuropathic pain is required as the 
first step. Indeed, typical CS conditions like fibromyal-
gia, or any other chronic pain condition not due to a 
lesion or disease of the somatosensory system, do not 
satisfy the criteria for the classification of neuropathic 
pain. Likewise, some patients with chronic low back 
pain, tennis elbow, or osteoarthritis may show features 
of CS, but do not fit into the diagnostic criteria for 
neuropathic pain. 
For a detailed description of the diagnostic criteria 
and clinical diagnosis of neuropathic pain, the readers 
are referred to the relevant international consensus 
documents (46,49,50). The main criteria for differen-
tiating between neuropathic and non-neuropathic CS 
pain are presented in Table 1.  
For the purpose of the present paper, it is impor-
tant to highlight the issue of sensory dysfunction in 
neuropathic versus non-neuropathic CS pain. Sensory 
testing is of prime importance for the diagnosis of neu-
ropathic pain (46,49). This includes testing of the func-
tion of sensory fibers with simple tools (e.g., a tuning 
fork for vibration, a soft brush for touch, and cold/warm 
objects for temperature), which typically assess the 
relationship between the stimulus and the perceived 
sensation (49). Several options arise here, all suggestive 
of neuropathic pain: hyperestesia, hypoestesia, hyper-
algesia, hypoalgesia, allodynia, paraesthesia, dyses-
thesia, aftersensations, etc. Again, the location of the 
sensory dysfunction is crucial for the differential clas-
sification between neuropathic and non-neuropathic 
CS pain. While in neuropathic pain the location of 
the sensory dysfunction should be neuroanatomically 
logical, in non-neuropathic CS pain it should be spread 
in nonsegmentally related areas of the body. In fact, 
clinical examination in non-neuropathic CS pain typi-
cally reveals increased sensitivity at sites segmentally 
unrelated to the primary source of nociception (25). 
Findings of numerous areas of hyperalgesia at sites 
Table 1. Criteria for the differential classification between neuropathic (46, 49,50) and non-neuropathic central sensitization (CS) 
pain.
Neuropathic pain Non-neuropathic CS pain
History of a lesion or disease of the nervous system No history of a lesion or disease of the nervous system
Evidence from diagnostic investigations to reveal an abnormality of 
the nervous system, or post-traumatic/postsurgical damage to the 
nervous system
No evidence from diagnostic investigations, or damage to the nervous 
system
Often related to an established medical cause like cancer, stroke, 
diabetes, herpes, or neurodegenerative disease
No medical cause for the pain established
Pain is neuroanatomically logical Pain is neuroanatomically illogical, i.e., located at sites segmentally 
unrelated to the primary source of nociception
Pain is often described as burning, shooting, or pricking Pain is not described as burning, shooting, or pricking, but most often 
as vague and dull
Location of the sensory dysfunction is neuroanatomically logical Location of the sensory dysfunction is neuroanatomically illogical, 
i.e., numerous areas of hyperalgesia at sites outside and remote to the 
symptomatic site – at segmentally unrelated sites 
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outside and remote to the symptomatic site, together 
with a nonsegmental general decrease in pressure pain 
threshold infers a generalized hyperexcitability of cen-
tral nociceptive pathways or CS (51). 
The presence of neuropathic pain does not exclude 
the possibility of CS or vice versa. In fact, some patients 
evolve from neuropathic pain with severe but local 
signs and symptoms, to a widespread pain condition 
that cannot be explained by neuropathic pain solely. 
In such cases, CS might account for the evolution to a 
widespread pain condition.  
Classification of Central Sensitization Pain
Once neuropathic pain has been eliminated as a 
reason, 2 options remain: the (chronic) pain arises from 
CS (i.e., CS dominates the clinical picture of the patient) 
or from dominance of peripheral somatic input (i.e., 
nociceptive pain). Some degree of central pain sensi-
tization in response to acute injury may be considered 
adaptive in facilitating recovery. Indeed, sensitization 
of local tissues is a feature of an acute inflammatory 
process (e.g., following an acute ankle sprain or muscle 
injury). When tissue is damaged, the responsiveness 
of polymodal nociceptive endings is enhanced by 
various substances released by various sources (such as 
serotonin released by platelets, bradykinin from the 
plasma, prostaglandins released by damaged cells, sub-
stance P released by the primary afferent fibers) (52). 
This process is called primary hyperalgesia or peripheral 
sensitization of nociceptors, and is a protective action 
of the human body to prevent use and consequent 
further damage of the traumatized and surrounding 
tissues. Secondary hyperalgesia refers to increased 
responsiveness of dorsal horn neurons localized in the 
spinal segment of the primary source of nociception. 
However, clinicians should aim to differentiate between 
adaptive peripheral sensitization, for example after an 
acute inflammatory process, and maladaptative central 
sensitization.
We propose the following criteria to facilitate this 
distinction clinically. The criteria should be evaluated 
together within the classification algorithm (Fig. 1). 
Musculoskeletal pain
Disproportionate pain experience?
no Central Sensitization  l  i i iDiffuse pain distribution?







no Central Sensitization  l  i i iCentral Sensitizationl  i i i
Fig. 1. Algorithm for the classification of  central sensitization (CS) pain. 
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These criteria are identifiable from the clinical history 
and examination. The underlying clincal rationale of 
these clinical criteria are considered in turn below. 
Criterion 1: Pain experience disproportionate 
to the nature and extent of injury or 
pathology 
This criterion is obligatory for the classification of 
CS pain. CS is typically characterized by disproportion-
ate pain, implying that the severity of pain and related 
reported or perceived disability (e.g., restriction and 
intolerance to daily life activities, to stress, etc.) are dis-
proportionate to the nature and extent of injury or pa-
thology (i.e., tissue damage or structural impairments) 
(1,4,7,9,12,13-16,19,32,42,53,54). This contradicts no-
ciceptive pain, where the severity of pain and related 
reported or perceived disability are proportionate to 
the nature and extent of injury or pathology. 
Screening of this first criterion implies that the 
clinician assesses 1) the patient’s amount of injury, pa-
thology, and objective dysfunctions capable of gener-
ating nociceptive input, and 2) the self-perceived pain 
and related disability. Next, the clinician then weighs 
both in order to answer the following question: Does 
this patient presents sufficient evidence of injury, pa-
thology, and/or objective dysfunctions for generating 
nociceptive input capable of causing the self-reported 
pain and disability? Several answers to this question 
are possible:
•	 Yes,	 this	 patient	 presents	 sufficient	 evidence	 of	
injury, pathology, and/or objective dysfunctions for 
generating nociceptive input capable of causing 
the self-reported pain and disability. This would 
imply that the patient has nociceptive pain, or at 
least a clinical picture dominated by nociceptive 
pain (Fig. 1). 
•	 No,	 this	 patient	 presents	 insufficient	 evidence	 of	
injury, pathology, or objective dysfunctions for 
generating nociceptive input capable of causing 
the self-reported pain and disability. This would 
imply that the patient fulfills this first out of 3 cri-
teria for CS pain; the patient may have CS pain. We 
proceed with screening of the remaining criteria. 
•	 There	 is	 evidence	 of	 injury,	 pathology,	 or	 objec-
tive dysfunctions for generating nociceptive input 
capable of causing pain and disability, but not 
enough for explaining the pain and disability ex-
perienced by this patient. Again, this would imply 
that the patient fulfills this first out of 3 criteria for 
CS pain; the patient may have CS pain. We proceed 
with screening of the remaining criteria. 
An example of disproprotionate pain may be a a 
patient with chronic neck pain, who suffered an ap-
parently minor injury, with no structural lesions on 
cervical scans, but a complex clinical picture of various 
symptoms, including segmentally unrelated pain areas 
and severe disability. This scenario is typically seen in 
patients with chronic whiplash associated disorders 
(grade 1 – 2) (1,3,4,32). 
Patients with osteoarthritis typically have (some) 
tissue damage (i.e., cartilage distruction), yet standard 
radiological findings show little or no association with 
pain severity or perceived disability (55). At the same 
time, mounting evidence supports an important role 
for CS in patients with osteoarthritis (8,17,55-58). 
In addition, there are patient cohorts with severe 
pain in the absence of any discernible tissue damage 
or pathology. In this group, nociception is not or has 
not been present, and yet they continue to have severe 
pain and related disability. This has been shown consis-
tently in studies of various patient populations, includ-
ing fibromyalgia (53), chronic fatigue syndrome (13,59), 
migraine (15), and chronic low back pain (7-9). It is clear 
that this group complies with this criterion. 
The presence of disproportionate pain implies 
some pain of central pain origin, but does not necessar-
ily reflect CS pain. Therefore, additional criteria should 
be met before one can consider CS as the dominant 
mechanism explaining the patient’s pain. 
Criterion 2: Diffuse pain distribution, 
allodynia, and hyperalgesia
This criterion addresses patient self-reported 
pain distribution as identified from the clinical history 
and/or a body chart (for instance, the Margolis Pain 
Diagram uses 2 body outlines, front and back, in which 
patients have to shade the body parts were they felt 
pain lasting for more than 24 hours in the past 4 weeks 
(60). At least one of the following, partly overlapping, 




•	 pain	 varying	 in	 (anatomical)	 location/traveling	
pain, including to anatomical locations unrelated 
to the presumed source of nociception e.g., hemi-
lateral pain, large pain areas with a nonsegmental 
(i.e., neuroanatomically illogical) distribution;
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•	 widespread	pain	(defined	as	pain	located	axial,	on	
the left and right side of the body and above and 
under the waist) (61); 
•	 and/or	 allodynia/hyperalgesia	 outside	 the	 seg-
mental area of (presumed) primary nociception 
(3,12,17,19,59). 
This overview of patterns of pain distribution is 
not comprehensive, but it provides a list of frequently 
occurring patterns considered indicative of CS, as they 
cannot be explained by a local nociceptive source. 
Criterion 2 is mainly screened through question-
ing, although allodynia/hyperalgesia can be examined 
on palpation or sensory testing as well (i.e., allodynia 
to non-noxious mechanical stimuli such as light touch 
and hyperalgesia to pin prick or heat and cold). Diffuse/
non-anatomic areas of pain/tenderness are typically 
found on palpation (40). Allodynia and/or hyperalge-
sia outside the segmental area of primary nociception 
has been used for establishing CS in studies of various 
chronic pain disorders (including whiplash, epicondyli-
tis, subacromial impingement syndrome, chronic fatigue 
syndrome, nonspecific arm pain) (3,12,17,19,21,59). In 
addition to manual palpation or assessing pressure pain 
thresholds, such allodynia/hyperalgesia outside the seg-
mental area of primary nociception can be established 
through history taking or questioning as well. For in-
stance, a low back pain patient reporting that wearing 
a necklace is no longer possible as it triggers pain.  
Here we propose criterion 1 as a go/no-go for the 
classification of CS pain. If criterion 1 and 2 are both 
met, then the classification of CS can be established. If 
only the first criterion (disproportionate pain) is met 
and not the second criterion, further screening of cri-
terion 3 is required.  
Criterion 3: Hypersensitivity of senses 
unrelated to the musculoskeletal system 
CS may reflect much more than generalized hy-
persensitivity to pain: It may be characterized by an in-
creased responsiveness to a variety of stimuli in addition 
to mechanical pressure (3,12,17,19,21,53,54,59), namely 
chemical substances (62), cold (21,42), heat (13,21), elec-
trical stimuli (32,53), stress (31,63-66), emotions, and 
mental load. Given the overall hyper-responsiveness 
of central nervous system neurons, CS may explain the 
hypersensitivity to many environmental (bright light, 
cold/heat, sound/noise, weather, stress, food [67-69]), 
and chemical stimuli (62,70,71) (odors, pesticides, medi-
cation among others). It is therefore recommended to 
question the patients with suspected CS for hypersen-
sitivity to bright light, sound, smell, and hot or cold 
sensations. For classification purposes, these symptoms 
should not have been present prior to the onset of the 
pain (disorder) of interest here. However, some of these 
could have been present before pain. Their premorbid 
presence does not exclude the possibility of CS pain, but 
makes them unreliable for diagnosing CS pain. 
Still, direct evidence showing that CS explains hy-
persensitivity to such environmental stimuli is lacking. 
This assumption is based on evidence from psychophysi-
ological studies showing hypersensitivity in pain pa-
tients to mechanical pressure (3,12,17,19,21,53,54,59), 
cold (21,42), heat (13,21), electrical stimuli (32,53), stress 
(31,63-66), food (67-69), chemical stimuli (62,70,71), and 
a study in patients with fibromyalgia where low thresh-
olds to auditory tones correlated with pressure pain 
thresholds (72). It is therefore recommended to ques-
tion the patients with suspected CS for hypersensitivity 
to bright light, sound, smell, and hot or cold sensations. 
The screening of criterion 3 can be done using part 
A of the Central Sensitization Inventory (44), which 
assesses symptoms common to CS, with total scores 
ranging from 0 to 100. Based on a validation study in 
a sample of 89 CS-pain patients and a 129 non-patient 
comparison group, a cutoff score of 40 is recommended 
(45). A cutoff score of 40 on the Central Sensitization 
Inventory provides a clinically relevant guide to alert 
health care professionals to the possibility that a pa-
tient’s symptom presentation may indicate the pres-
ence of CS pain (45). Still, establishing CS pain in clinical 
situations should not rely on self-report only, and there 
is currently no published work comparing the Central 
Sensitization Inventory between CS and neuropathic 
pain patients. Hence, we have no direct evidence to 
support the use of the Central Sensitization Inventory 
as the sole criterion for classifying CS pain, and have 
therefore chosen to integrate its use in a more compre-
hensive approach to classifying CS pain.  
Here we propose that the combination of a score 
of at least 40 on the Central Sensitization Inventory, 
together with disproportionate pain (criterion 1), suf-
fices for the classification of CS pain in patients with 
non-neuropathic pain (Fig. 1). 
Additional Signs and Symptoms Often Seen 
in Patients with CS, but Not Required for the 
Classification 
Clearly, patients with CS typically present with many 
more signs and symptoms than those included in the 3 
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classification criteria for CS. For instance, the longer pain 
persists, the more likely CS becomes a more dominant 
component to the clinical presentation (73). An abnor-
mal timeline is defined as a course over time that devi-
ates from the natural course of the illness or injury. Table 
2 lists a number of additional signs and symptoms often 
seen in patients with CS pain. Some of them partly over-
lap with one or more of the classification criteria for CS 
pain. Others are totally new and did not make it into the 
classification criteria, either because our clinical and re-
search experience indicates that their prevalence among 
patients with CS is too low, or because they are not 
specific for CS. Taken together, the additional signs and 
symptoms have low sensitivity or specificity for patients 
with CS, and are mainly included here for clarity reasons. 
If present, they may strengthen the classification of CS 
pain, but only if they have not been present prior to the 
onset of the pain (disorder) of interest. 
In addition to the signs and symptoms listed in Table 
2, it is often informative to question the patient about 
the short-term and long-term therapeutic responses to 
previous or ongoing treatments. The following options 
can be regarded as an abnormal therapeutic response: 
nonresponders to nociception-targeted treatments pro-
vided, inconsistent or unpredictable response to treat-
ment, intolerance to various treatment approaches, or 
an acute increase in hypersensitivity to various stimuli 
in response to (new) treatment, including symptom 
exacerbation beyond what is regularly seen in patients 
with local (nociceptive) pain disorders (25,73).  
Finally, we acknowledge the close association be-
tween CS and maladaptive psychosocial factors (e.g., 
negative emotions, poor self-efficacy, maladaptive 
beliefs and pain behaviors), as evidenced in the study 
by Smart et al (39). Indeed, “cognitive emotional sensi-
tization” (74) refers to the capacity of forebrain centers 
of exerting powerful influences on various nuclei of the 
brainstem, including the nuclei identified as the origin 
of the descending facilitatory pathways (75). The activ-
ity in descending pathways is not constant but can be 
modulated, for example by the level of vigilance, cata-
strophizing, depression, attention, and stress (76,77). 
Table 2. Additional signs and symptoms often seen in patients with central sensitization (CS), but not required for the classification 
of  CS pain.
Sign or symptom Assessment Description
Numbness Questioning and/or clinical examination Numbness not localized and with nonsegmental distribution
Muscle weakness Questioning and/or clinical examination Subjective sensation of weakness in whole limb/lack of muscle control in whole limb
Cognitive deficits Questioning and/or clinical examination
Concentration difficulties, short-term memory 
disturbances, latency, difficulties finding the correct 
words, “brain fog”
Sleeping difficulties Questioning Difficulty falling asleep, frequent awakenings at night, unrefreshing sleep
Inconsistent clinical examination findings Clinical examination Inconsistent findings across clinical tests 
Phantom swelling sensation Questioning and/or clinical examination Sensation of swollen limb in absence of visual evidence of edema or swelling
Phantom swelling enhancement Questioning and/or clinical examination Phantom swelling sensations enhance when the patients close their eyes
Phantom swelling diminishment Questioning and/or clinical examination Phantom swelling sensations decrease or disappear when they view the affected limb
Altered perception of affected body part Questioning and/or clinical examination
Perception that the affected body part is smaller or 
larger than it should be, or inability to feel part of the 
affected body region without visual or tactile input
Impaired tactile localization Questioning and/or clinical examination
Decreased tactile acuity of (the skin above) the 
affected region; increased 2-point discrimination 
threshold
Phantom stiffness Questioning and/or clinical examination Sensation of joint stiffness in absence of objective signs of decreased mobility
Dyskinaesthesia Questioning and/or clinical examination Sensation of clumsiness or poor spatial acuity or less aware of where their limbs are in space
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In spite of the evidence pointing to an important 
role for maladaptive psychosocial and emotional fac-
tors in the etiology and maintenance of the process of 
CS, we chose against including them in the criteria for 
classification of CS pain. The reason is based on research 
findings showing that depressive symptoms, anxiety, or 
catastrophizing are neither related to pain sensitivity or 
brain activity during experimental pain in chronic pain 
patients (78). In addition, the lack of sensitivity and 
specificity of maladaptive psychosocial and emotional 
factors for the classification of CS pain is an important 
issue. Maladaptive psychosocial and emotional factors 
can be present in chronic pain patients without CS as 
well, making them inappropriate for inclusion as a 
classification criterion. Likewise, patients with clear evi-
dence of CS sometimes do not have negative emotions, 
maladaptive beliefs, or pain behaviors, indicating their 
low sensitivity for the classification of CS in patients 
with chronic pain. Nevertheless, the authors recognize 
the importance of assessing and addressing these psy-
chosocial and emotional factors in the treatment ap-
proach of any pain patient.
Discussion
This is the first presentation of criteria and an 
algorithm for the clinical classification of CS in pain 
patients, supported by a large volume of research find-
ings (1-4,8,12,14,15,32,39-42,45,53,59,62,73). Moreover, 
guidelines for the differential classification between 
neuropathic, nociceptive, and CS pain are proposed. 
In all 3 pain types a biopsychosocial view is warranted; 
in all 3 pain types a multimodal model is necessary to 
explain the pain (intensity) and to choose the appropri-
ate treatment. 
In addition, criterion 3 from the classification 
criteria proposed here is supported by a large valida-
tion study of the Central Sensitization Inventory, using 
patients with various CS diagnoses like restless leg syn-
drome, chronic fatigue syndrome, temporomandibular 
disorders, tension headaches, migraines, fibromyalgia, 
irritable bowel syndrome, and multiple chemical sensi-
tivity syndromes (45). Finally, the classification criteria 
are directly substantiated by a study of a large group of 
patients with low back pain (n = 464) (40). Two of the 
4 signs/symptoms that differentiated the CS low back 
pain patients from the neuropathic and nociceptive 
pain groups are included in the 4 major classification 
criteria for CS: pain disproportionate to the nature and 
extent of injury or pathology, and diffuse/nonanatomic 
areas of pain/tenderness on palpation (40). In addition 
to these 2 signs/symptoms, a third sign (disproportion-
ate, non-mechanical, unpredictable pattern of pain 
provocation in response to multiple/nonspecific ag-
gravating/easing factors), although rather specific for 
spinal pain, is partly included in criteria 2 and 3. 
In addition to the scientific evidence presented, 
these classification criteria are supported by expert 
consensus. Eighteen pain experts from 13 institutions 
across 7 countries combine over 100 years of clinical and 
scientific experience in patients with chronic pain, and 
over 200 scientific publications in the field of chronic 
pain. That said, the classification algorithm still requires 
validation in clinical settings, including examination of 
its clinical applicability. The inter- and intra-examiner 
test-retest reliability, sensitivity, specificity, positive, and 
negative likelihood ratios of the classification criteria 
presented here remain to be examined. In addition, the 
classification algorithm lacks “objective” criteria, but 
for the time being there is little proof for an objective 
biomarker for CS pain. However, this is the first step 
towards a set of classification criteria and a classifica-
tion algorithm for CS pain. We hope our proposal will 
facilitate the acknowledgment and recognition of 
CS, research in this area, and eventually adaptation/
improvement of the classification algorithm based on 
research data.     
If a clinician recognizes CS in a patient with chronic 
pain, how does it potentially impact upon treatment? 
The presence of CS implies that the brain produces pain, 
fatigue, and other warning signs even when there is no 
real tissue damage. CS is not a disorder of the mind, but 
rather a disease of the brain and spinal cord. Hence, 
the brain should become an important treatment tar-
get. This can be achieved by explaining to the patient 
the mechanism of CS with evidence from modern neu-
roscience, an approach with high patient satisfaction 
(79-81), and has proven to be effective in a variety of 
chronic pain populations (80). Neuroscience education 
enables patients to understand the controversy sur-
rounding their pain, including the lack of objective bio-
markers, and the need for a time-contingent approach 
to activity and exercise therapy. A symptom-contingent 
approach may facilitate the brain in its production of 
nonspecific warning signs, while a time-contingent ap-
proach might deactivate brain-orchestrated descending 
facilitatory pathways. This view is supported by findings 
of reduced central nervous system hyperexcitability 
(37), and an increase in prefrontal cortical volume (38) 
in response to time-contingent therapy in chronic pain 
(fibromyalgia) patients. 
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In addition, centrally-acting drugs, like selective 
and balanced serotonin and norepinephrine reuptake 
inhibitor drugs, the serotonin precursor tryptophan, 
opioids, NMDA-receptor antagonists, and calcium 
channel a2δ ligands, are indicated for the treatment of 
CS (82). For more indepth guidelines on the treatment 
of CS in patients with chronic pain, the readers are re-
ferred to other sources (16,23,24,56,81,82).
conclusion
The awareness is growing that CS is of prime 
importance for the management of chronic pain, but 
its classification is challenging clinically since no gold 
standard method of assessment exists. It is proposed 
that the classification of CS pain entails 2 major steps: 
the exclusion of neuropathic pain and the differential 
classification of nociceptive versus CS pain. For the 
former, the International Association for the Study of 
Pain diagnostic criteria (46) are available for diagnosing 
or excluding neuropathic pain, although they require 
validation work as well. For the latter, clinicians are ad-
vised to screen their patients for 3 major classification 
criteria, and use them to complete the classification 
algorithm for each individual patient with chronic pain. 
Although based on both research findings and expert 
opinion, the classification algorithm requires experi-
mental testing in future studies.  
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